These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34155573)

  • 21. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
    Simon D; Tascilar K; Fagni F; Krönke G; Kleyer A; Meder C; Atreya R; Leppkes M; Kremer AE; Ramming A; Pachowsky ML; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Berking C; Sticherling M; Neurath MF; Schett G
    Ann Rheum Dis; 2021 Oct; 80(10):1312-1316. PubMed ID: 33958324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study.
    Wang W; Wang YH; Huang CH; Hsieh TH; Ibarburu GH; Wei JC
    BMC Med; 2024 Mar; 22(1):117. PubMed ID: 38481216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease.
    Perdan-Pirkmajer K; Thallinger GG; Snoj N; Čučnik S; Žigon P; Kveder T; Logar D; Praprotnik S; Tomšič M; Sodin-Semrl S; Ambrožič A
    Lupus; 2012 Feb; 21(2):175-83. PubMed ID: 22235050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study.
    Lampasona V; Secchi M; Scavini M; Bazzigaluppi E; Brigatti C; Marzinotto I; Davalli A; Caretto A; Laurenzi A; Martinenghi S; Molinari C; Vitali G; Di Filippo L; Mercalli A; Melzi R; Tresoldi C; Rovere-Querini P; Landoni G; Ciceri F; Bosi E; Piemonti L
    Diabetologia; 2020 Dec; 63(12):2548-2558. PubMed ID: 33029657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of delayed second dose of AZD1222 vaccine in patients with autoimmune rheumatic disease.
    Mehta P; Paul A; Ahmed S; Cherian S; Panthak A; Benny J; Shenoy P
    Clin Rheumatol; 2022 Nov; 41(11):3537-3542. PubMed ID: 35760938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Risk Factors During First and Second Wave of COVID-19 in Patients with Autoimmune Rheumatic Diseases (AIRD): Results from KRACC Subset.
    Jain V; Shobha V; Kumar S; Janardana R; Selvam S
    Mediterr J Rheumatol; 2023 Sep; 34(3):342-348. PubMed ID: 37941863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients.
    Yang L; Xu Q; Yang B; Li J; Dong R; Da J; Ye Z; Xu Y; Zhou H; Zhang X; Liu L; Zha Y; Yu F
    BMC Microbiol; 2021 Dec; 21(1):351. PubMed ID: 34922455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumococcal antibody protection in patients with autoimmune inflammatory rheumatic diseases with varying vaccination status.
    Rasmussen SL; Fuursted K; Nielsen KA; Laurberg NP; Sørensen MB; Fagerberg SK; Leutscher P; Rasmussen C
    Scand J Rheumatol; 2020 Sep; 49(5):353-360. PubMed ID: 32468899
    [No Abstract]   [Full Text] [Related]  

  • 30. COVID-19 Infection In Patients With Autoimmune Rheumatic Diseases: Patient's Perspective And Descriptive Analysis From A Lower-Middle-Income Country.
    Riaz M; Ishaq S; ; Jibril H; Zafar Mahmood SB; Riaz M
    J Pak Med Assoc; 2023 Oct; 73(10):2059-2061. PubMed ID: 37876070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.
    D'Silva KM; Serling-Boyd N; Hsu TY; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2021 Jun; 80(6):817-819. PubMed ID: 33436385
    [No Abstract]   [Full Text] [Related]  

  • 32. Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'.
    C SK; Ahmed S; Shenoy V; Menon AR; Saijan S; Babu SA; Shenoy P
    Ann Rheum Dis; 2023 Jun; 82(6):e130. PubMed ID: 33692021
    [No Abstract]   [Full Text] [Related]  

  • 33. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
    Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
    Front Immunol; 2021; 12():723585. PubMed ID: 34489974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset.
    Chebbi P; Shobha V; Rao VK; Haridas V; Janardana R; Pinto B; Kumar S; Patil A; Tekkatte R; Salanke M; Mahendranath KM
    BMC Rheumatol; 2023 Jul; 7(1):22. PubMed ID: 37496101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial.
    Ren L; Fan G; Wu W; Guo L; Wang Y; Li X; Wang C; Gu X; Li C; Wang Y; Wang G; Zhou F; Liu Z; Ge Q; Zhang Y; Li H; Zhang L; Xu J; Wang C; Wang J; Cao B
    Clin Infect Dis; 2021 May; 72(10):e545-e551. PubMed ID: 32840287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of COVID-19 Pandemic on Patients With Rheumatic Diseases in Medina, Saudi Arabia: An Observational Cross-Sectional Study.
    Safar Alsofyani I; Samman BS; Alhubayshi SS; Ellahi AT; Alsaedi AB; Almansour M
    Cureus; 2024 May; 16(5):e60128. PubMed ID: 38864060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy.
    Lledó A; Retuerto M; Almendro-Vázquez P; Fernández-Ruiz M; Galindo M; Laguna-Goya R; Paz-Artal E; Lalueza A; Aguado JM; Pablos JL
    Semin Arthritis Rheum; 2021 Dec; 51(6):1258-1262. PubMed ID: 34775160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens.
    Rezaei M; Sadeghi M; Korourian A; Tabarsi P; Porabdollah M; Askari E; Mortaz E; Mahmoudi S; Marjani M; Velayati AA
    Hum Antibodies; 2021; 29(2):109-113. PubMed ID: 33720878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey.
    Cherian S; Paul A; Ahmed S; Alias B; Manoj M; Santhosh AK; Varghese DR; Krishnan N; Shenoy P
    Rheumatol Int; 2021 Aug; 41(8):1441-1445. PubMed ID: 34142203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.